Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference
October 30, 2023 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO
October 27, 2023 05:30 ET
|
Opthea Limited
Dr. Megan Baldwin transitions to Founder, Chief Innovation Officer and remains on the Board of Directors Experienced pharmaceutical executives Dr. Frederic Guerard appointed as CEO and Peter...
Diabetic Retinopathy Market to Register Incremental Growth by 2032, Asserts DelveInsight | Leading Companies in the Market - Opthea, Regenxbio, Kodiak, Ocuphire, Eisai, Apexian, Oculis, Bayer, Novartis, Allegro
October 11, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Diabetic Retinopathy Market to Register Incremental Growth by 2032, Asserts DelveInsight | Leading Companies in the Market - Opthea, Regenxbio,...
Diabetic Macular Edema Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies to Watch Out - Novartis, Roche, Kodiak, Oxurion, Ocuphire, Bausch Health, KalVista, Allegro Opthalmics
October 04, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Diabetic Macular Edema Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies to Watch Out - Novartis, Roche, Kodiak,...
Opthea to Participate at the 2023 Euretina Congress
October 02, 2023 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)
August 28, 2023 05:30 ET
|
Opthea Limited
OPT has successfully completed the placement and institutional entitlement offer components of its previously announced capital raisingAs a result of strong demand from both existing and new domestic...
Age-Related Macular Degeneration Market to Grow Rapidly by 2032, Predicts DelveInsight | Key Companies - Opthea, Kodiak, Outlook, Apellis, Alkeus, Iveric Bio, Novartis, Luxa Biotechnology, AstraZeneca, Annexon, REGENXBIO
August 21, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Age-Related Macular Degeneration Market to Grow Rapidly by 2032, Predicts DelveInsight | Key Companies - Opthea, Kodiak, Outlook, Apellis, Alkeus,...
Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302
July 26, 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, July 26, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea to Present at the 2023 Ophthalmology Innovation Summit
July 24, 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...